LUPIN

Fundamental View-

Lupin Ltd., established in 1968 and headquartered in Mumbai, has delivered a strong turnaround with consolidated revenue rising ~20% year-over-year to ₹20,011 crore in FY 2023–24 and net profit of ₹1,936 crore (up dramatically from a loss of ₹1,510 crore in FY 2022–23). The company is well-positioned both domestically and internationally—holding the #3 spot by U.S. prescription volume and ranking 7th in the Indian pharma market. Lupin continues to invest heavily in R&D (₹1,526 crore in FY 24, 7.8% of revenue), with 440 patents granted and 506 approvals under its complex generics and biosimilars pipeline. Technical View- As seen on the weekly chart, Lupin has witnessed consistent buying momentum since the start of the week. Currently, the stock is trading within the range of its 14-day and 55-day EMA, indicating consolidation with positive undertones. On July 3rd, the stock made a low of ₹1905, from where a sharp recovery was observed. Even on Friday, the stock opened at ₹1962, made a low of ₹1957, touched a high of ₹1996, and closed positively at ₹1980. Both the MACD and RSI are reflecting building positive strength, confirming a bullish trend in progress. In the short term, the stock is facing a minor resistance near the ₹2000 mark, but given the strong rally and technical structure, any dip towards the ₹1950 zone may present a good buying opportunity with a stop-loss of ₹1950. On the upside, the stock is expected to test levels of ₹2025–₹2030 in the coming sessions. Warning- ***** ***** *****